Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

(2013) Rashmi R. Shah et al.   DRUG SAFETY

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity

(2013) Lars Harbaum et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors

(2013) Colin F Spraggs et al.   PHARMACOGENOMICS

Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence

(2012) Yi Ling Teo et al.   BREAST CANCER RESEARCH AND TREATMENT

Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis

(2012) Yi Ling Teo et al.   CANCER TREATMENT REVIEWS

Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity

(2012) Kei Kunimasa et al.   INTERNAL MEDICINE

Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure

(2012) Hans M. Westgeest et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction

(2012) Jane R. Kenny et al.   PHARMACEUTICAL RESEARCH

Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib

(2011) H. Takakusa et al.   DRUG METABOLISM AND DISPOSITION

Central role of mitochondria in drug-induced liver injury

(2011) Dominique Pessayre et al.   DRUG METABOLISM REVIEWS

Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review

(2011) Y.-C. Lai et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Safe and Successful Treatment With Erlotinib After Gefitinib-Induced Hepatotoxicity: Difference in Metabolism As a Possible Mechanism

(2011) Takashi Kijima et al.   JOURNAL OF CLINICAL ONCOLOGY

HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer

(2011) Colin F. Spraggs et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile

(2010) X. Li et al.   DRUG METABOLISM AND DISPOSITION

Successful Treatment With Erlotinib After Gefitinib-Related Severe Hepatotoxicity

(2010) Masayuki Takeda et al.   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib in a Patient With Postnecrotic Liver Cirrhosis Related to Imatinib

(2010) Vito Spataro   JOURNAL OF CLINICAL ONCOLOGY

Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma

(2010) Chun-Fang Xu et al.   JOURNAL OF HEPATOLOGY

Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity

(2010) Geoffrey Y. Ku et al.   LUNG CANCER

Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

(2010) W. C. Teng et al.   MOLECULAR PHARMACOLOGY

Deleterious Effects of Reactive Metabolites

(2010) Sabry M. Attia   Oxidative Medicine and Cellular Longevity

An Acute Hepatitis Resembling Autoimmune Hepatitis Occurring During Imatinib Therapy in a Gastrointestinal Stromal Tumor Patient

(2009) Sandra Aliberti et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities

(2009) Xiaohai Li et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways

(2009) X. Li et al.   DRUG METABOLISM AND DISPOSITION

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

(2009) Craig Lammert et al.   HEPATOLOGY

Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors

(2009) Onder Tonyali et al.   MEDICAL ONCOLOGY

Unintended Hepatic Adverse Events Associated with Cancer Chemotherapy

(2009) John R. Senior   TOXICOLOGIC PATHOLOGY